Exodus Point Capital Management, LP Mirati Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$27.8 - $45.35 $2.38 Million - $3.87 Million	-85,445 Reduced 86.54%	13,293 $579,000
Q2 2023 Aug 10, 2023	SELL	$36.13 - $49.49 $2.35 Million - $3.22 Million	-65,004 Reduced 39.7%	98,738 $3.57 Million
Q1 2023 May 11, 2023	BUY	$36.54 - $54.26 $5.27 Million - $7.83 Million	144,328 Added 743.42%	163,742 $6.09 Million
Q4 2022 Feb 13, 2023	SELL	$41.27 - $98.62 $824,904 - $1.97 Million	-19,988 Reduced 50.73%	19,414 $880,000
Q3 2022 Nov 10, 2022	BUY	$59.5 - $86.7 $2.34 Million - $3.42 Million	39,402 New	39,402 $2.75 Million
Q2 2022 Aug 19, 2022	SELL	$39.16 - $88.71 $1.52 Million - $3.45 Million	-38,927 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $1.52 Million - $3.03 Million	20,046 Added 106.17%	38,927 $3.2 Million
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $2.49 Million - $3.59 Million	18,881 New	18,881 $2.77 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $3.4 Million - $4.56 Million	-25,713 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $2.56 Million - $3.2 Million	17,811 Added 225.4%	25,713 $4.15 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $62,137 - $86,649	-391 Reduced 4.71%	7,902 $1.35 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $1.34 Million - $1.99 Million	8,293 New	8,293 $1.82 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $1.72 Million - $2.87 Million	-23,854 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $1.66 Million - $2.77 Million	23,854 New	23,854 $1.83 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.